EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating Dermatological Side Effects of COVID‐19 Vaccination Among the Bangladeshi Population

Sumaya Tabassum, M. Rakibul Hasanur Roni, Md. Tahalil Islam Rahat, Most. Shermin Akter Sumi, Most. Nusrat Jahan Resma, Md Ashiqur Rahman Bhuiyan, Md. Kaderi Kibria

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/9521685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 16.04.2026. Verfasst von Sumaya Tabassum und 6 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While the safety profile of COVID‐19 vaccines has been extensively evaluated, dermatological adverse events remain insufficiently characterized, particularly in low‐ and middle‐income countries. Existing studies in Bangladesh primarily focus on systemic postvaccination effects, with limited attention to cutaneous manifestations, their functional impact, and dose‐related patterns. This study aimed to comprehensively assess the prevalence and determinants of dermatological side effects following COVID‐19 vaccination among the Bangladeshi population.

Methods

A nationwide cross‐sectional study was conducted from January 1 to March 1, 2025, involving 819 adults (aged ≥ 18) who had received at least one dose of a COVID‐19 vaccine. A multistage sampling strategy ensured geographic and demographic representativeness. Detailed information on pre‐existing dermatological conditions, postvaccination cutaneous symptoms, timing, and functional impact was collected using a structured questionnaire. Multivariable logistic regression was used to identify predictors of dermatological side effects, and model discrimination was evaluated using receiver operating characteristic (ROC) analysis.

Results

Overall, 66.3% of participants reported at least one dermatological reaction following vaccination. The most frequently reported manifestations were itching (32.8%), rash (28.4%), psoriasis (10.8%), and eczema (10.4%). These side effects affected daily activities in 62.2% of cases, particularly work (40.9%) and social life (36.2%). Age, vaccine type, and number of doses received were significant predictors ( p < 0.05). Individuals under 20 and over 60 had higher risk ( p = 0.005), and those receiving ≥ 3 doses had significantly increased odds of side effects ( p < 0.001). AstraZeneca recipients reported more dermatological reactions than those receiving Pfizer, Moderna, or Sinopharm. The predictive model showed good performance (AUC = 0.794).

Conclusion

Dermatological side effects following COVID‐19 vaccination are common, clinically heterogeneous, and frequently disrupt daily functioning in the Bangladeshi population. The observed associations with vaccine type and cumulative dosing highlight the need for dermatology‐informed vaccine safety surveillance and targeted patient counseling to support sustained vaccine confidence.

Zitieren

APA

Tabassum, S., Roni, M. R. H., Rahat, M. T. I., Sumi, M. S. A., Resma, M. N. J., Bhuiyan, M. A. R., & Kibria, M. K. (2026). Investigating Dermatological Side Effects of COVID‐19 Vaccination Among the Bangladeshi Population. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/9521685

Vancouver

Tabassum S, Roni MRH, Rahat MTI, Sumi MSA, Resma MNJ, Bhuiyan MAR, et al. Investigating Dermatological Side Effects of COVID‐19 Vaccination Among the Bangladeshi Population. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/9521685

BibTeX
@article{Tabassum2026,
  author = {Tabassum, Sumaya and Roni, M. Rakibul Hasanur and Rahat, Md. Tahalil Islam and Sumi, Most. Shermin Akter and Resma, Most. Nusrat Jahan and Bhuiyan, Md Ashiqur Rahman and Kibria, Md. Kaderi},
  title = {Investigating Dermatological Side Effects of COVID‐19 Vaccination Among the Bangladeshi Population},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/9521685}
}
Kostenlos starten →